Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.
Ignacio Blanco, MD, PhD
Advertisement
Ignacio Blanco, MD, PhD
Articles by Ignacio Blanco, MD, PhD
Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5